ライフサイエンスコーパス: inactivated vaccine

1 sus nonadjuvanted H5N1 avian influenza virus inactivated vaccine.

2 for the live vaccine was higher than for the inactivated vaccine.

3 ccine had significantly better efficacy than inactivated vaccine.

4 rtion of residents have been inoculated with inactivated vaccine.

5 to individuals with completed primary series inactivated vaccine.

6 cinated participants after they received the inactivated vaccine.

7 sters in these populations who received this inactivated vaccine.

8 03-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine.

9 as well as concurrent receipt compared with inactivated vaccine.

10 candidate for the development of novel PRRS inactivated vaccine.

11 tenfold higher than those from the licensed inactivated vaccine.

12 three doses of a licensed, adjuvanted human inactivated vaccine.

13 se (HD) and the standard-dose (SD) trivalent inactivated vaccine.

14 e efficacy of 60% (95% CI, 33 to 77) for the inactivated vaccine.

15 ein vaccines are a desirable alternative for inactivated vaccines.

16 otected against a respiratory challenge than inactivated vaccines.

17 ilities for safe and inexpensive subunit and inactivated vaccines.

18 tive when elicited by live organisms than by inactivated vaccines.

19 ponses after immunization with either DNA or inactivated vaccines.

20 influenza vaccines to 68.9% (53.6-79.2) for inactivated vaccines.

21 cine) in adults primed with viral vector and inactivated vaccines.

22 dies to assess response to the adenoviral or inactivated vaccines.

23 egies, especially in populations primed with inactivated vaccines.

24 This publication focused on inactivated vaccines.

25 ng mainly on data from the United States and inactivated vaccines.

26 ity but have reduced safety when compared to inactivated vaccines.

27 for yearly reformulation of strain-specific inactivated vaccines.

28 ination and simultaneous receipt of selected inactivated vaccines.

29 ticipants who received one to three doses of inactivated vaccine 1-2 years after infection (infected-

30 la vaccine (3625 pfu) or of a partially heat-inactivated vaccine (1125 or 439 pfu).

31 ated vaccine than in the group that received inactivated vaccine (153 vs. 338 cases, P<0.001).

32 ated vaccine (3.8%) than among recipients of inactivated vaccine (2.1%, P=0.076).

33 However, current inactivated vaccines administered by intramuscular injec

34 iology recommend influenza immunization with inactivated vaccine (administered intramuscularly) as pa

35 za virus vaccines and of large quantities of inactivated vaccines after the emergence or reemergence

36 The absolute efficacy of the inactivated vaccine against both types of virus was 77%

37 The recommended vaccination schedule was inactivated vaccine against diphtheria, tetanus, pertuss

38 1967, two toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus

39 Administration of a formalin inactivated vaccine against RSV to children in the 1960s

40 inical studies have indicated that subvirion inactivated vaccines against avian influenza viruses, pa

41 pear to be different for live-attenuated and inactivated vaccines among children aged 2-8 years, alth

42 a A virus was 72% (95% CI, 49 to 84) for the inactivated vaccine and 29% (95% CI, -14 to 55) for the

43 confidence interval [CI], 46 to 81) for the inactivated vaccine and 36% (95% CI, 0 to 59) for the li

44 eriod of peak influenza activity was 56% for inactivated vaccine and 47% for attenuated vaccine.

45 g 78%, 88%, and 53% of children who received inactivated vaccine and among 55%, 79%, and 30% of child

46 his vaccine response, we immunized mice with inactivated vaccine and injected Ag-pulsed activated APC

47 rotein candidates for development of a safer inactivated vaccine and provides insight into the divers

48 hes currently being tested include subvirion inactivated vaccines and cold-adapted, live attenuated v

49 ous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines.

50 were immunogenic in animals vaccinated with inactivated vaccines and subsequently protected against

51 Separate estimates were calculated for the inactivated vaccines and the live attenuated vaccine.

52 ce has accrued on the protection afforded by inactivated vaccines and the safety and efficacy in chil

53 ) and all-cause mortality between CoronaVac (inactivated vaccine) and BNT162b2 (mRNA-based vaccine).

54 d trial involving healthy adults showed that inactivated vaccine appeared to be efficacious, whereas

55 Inactivated vaccines are available but require multiple

56 Adjuvanted whole inactivated vaccines are given intramuscularly in variou

57 andemic antigens, particularly H5, subvirion inactivated vaccines are poorly immunogenic, for reasons

58 ncy of an influenza A/Puerto Rico/8/34 virus inactivated vaccine as a poly(I.C)- or a squalene-based

59 firmed influenza among subjects who received inactivated vaccine as compared with those given live at

60 ive attenuated vaccines for young chicks and inactivated vaccines as boosters for laying hens.

61 was 63% (95% CI, 45 to 75; P<0.001) for the inactivated vaccine, as compared with -19% (95% CI, -113

62 last vaccine received was live compared with inactivated vaccine, as well as concurrent receipt compa

63 cally not as efficient as live attenuated or inactivated vaccines at inducing protective immune respo

64 The MF59 adjuvanted trivalent inactivated vaccine (ATIV) was developed to increase the

65 BBV152 is a whole-virion inactivated vaccine based on the Asp614Gly variant.

66 nicity after a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (A

67 These findings show that inactivated vaccine BBV152 induces robust immune memory

68 ine on day 85; the same regimen but with the inactivated vaccine being adjuvanted with AS03; and an A

69 However, better inactivated vaccines, better rapid diagnostic tests, and

70 nesia/5/2005) followed by an H5N1 monovalent inactivated vaccine boost at 4, 8, 12, 16, or 24 weeks t

71 nd its priming immune responses with an H5N1 inactivated vaccine boost.

72 d vaccine was slightly less than that of the inactivated vaccine, but not statistically greater than

73 The adjuvanted inactivated vaccine, but not the live-attenuated vaccine

74 IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may

75 etter cross-protective immune responses than inactivated vaccines by eliciting local mucosal immunity

76 d West Nile viruses, and vaccination with an inactivated vaccine can effectively prevent disease.

77 ian influenza vaccine usage, and efficacious inactivated vaccines can be developed using antigenic va

78 Our results using inactivated vaccine candidates from the human pandemic p

79 ctively) and for those who received live and inactivated vaccines concurrently compared with inactiva

80 owever, well-tolerated and immunogenic, with inactivated vaccines containing 15mug of HA generally in

81 dividuals immunized with a poorly protective inactivated vaccine contracted measles, and was postulat

82 Whole virion inactivated vaccine CoronaVac (C) and Spike (S) mRNA BNT

83 onses in 111 individuals vaccinated with the inactivated vaccine CoronaVac and 111 COVID-19 patients

84 immunization of the homologous or Sw/Iowa/30-inactivated vaccine developed HI and VN antibodies to th

85 AV) in the United States is hindered because inactivated vaccines do not provide robust cross-protect

86 cohort study suggest that immunization with inactivated vaccines during natalizumab therapy was both

87 In addition, antibodies elicited by inactivated vaccines effectively neutralized the cytotox

88 ve among children in a year with substantial inactivated vaccine effectiveness.

89 serologic end point alone will overestimate inactivated vaccine efficacy.

90 e, through strategies that included seasonal inactivated vaccines, Flumist, and synthetic peptides de

91 a wild type hemagglutinin and the commercial inactivated vaccine, FluSure.

92 onstrated that mice receiving a conventional inactivated vaccine followed by a skin-applied dissolvin

93 03-adjuvanted, chimeric H8/1, intramuscular, inactivated vaccine followed by an AS03-adjuvanted, chim

94 An ideal inactivated vaccine for influenza A virus would induce n

95 Formalin-inactivated vaccines for EEEV and WEEV are also poorly i

96 ality, yet the systems to produce high yield inactivated vaccines for these viruses have lagged behin

97 advantages that may speed the development of inactivated vaccines for use in humans and potentially l

98 es for use in humans and potentially live or inactivated vaccines for use in nonhuman primates at ris

99 recommend to start crucial vaccinations with inactivated vaccines from 3 months after transplant, irr

100 Most notably, immunization with inactivated vaccines generated in vivo protective immuni

101 Inactivated vaccines given to European travelers were fo

102 intervention, subjects with influenza in the inactivated vaccine group were less likely than those in

103 injection site) were observed in 27% of the inactivated vaccine group, and coryza (12%) and sore thr

104 Nearly all recipients of inactivated vaccine had postvaccination titers of at lea

105 High-dose (HD) trivalent inactivated vaccine has increased immunogenicity in olde

106 ith inactivated alone or concurrent live and inactivated vaccines (HR, 0.50; 95% confidence interval

107 influenza vaccines in Homo sapiens, the i.m. inactivated vaccine (IIV/Fluzone) and the live attenuate

108 ain (H1/stalk) following trivalent influenza inactivated vaccine (IIV3) immunization in pregnant wome

109 ain (H1/stalk) following trivalent influenza inactivated vaccine (IIV3) vaccination in pregnant women

110 e effectiveness of quadrivalent to trivalent inactivated vaccines (IIV4 to IIV3, respectively) agains

111 administered influenza vaccine) or trivalent inactivated vaccine in a double-blind manner.

112 included, efficacy was demonstrated for the inactivated vaccine in a year with low influenza attack

113 weeks to that of 2 doses of H5N1 monovalent inactivated vaccine in adults.

114 e attenuated influenza vaccine with those of inactivated vaccine in infants and young children.

115 s of age (6.1%) than among the recipients of inactivated vaccine in this age group (2.6%, P=0.002).

116 eradication and the potential role played by inactivated vaccine in this setting.

117 against the virus conferred by different H7 inactivated vaccines in chickens.

118 tibodies at similar levels compared to whole inactivated vaccines in female mice with and without pri

119 lative efficacies of the live attenuated and inactivated vaccines in preventing laboratory-confirmed

120 We found that vaccination with adjuvanted, inactivated vaccines induced a very broad antibody respo

121 e measure of successful vaccination with the inactivated vaccine is a systemic rise in immunoglobulin

122 These results suggest that this inactivated vaccine is effective against the three encep

123 The available inactivated vaccine is effective for preventing influenz

124 A formalin-inactivated vaccine is not suitable for these viruses be

125 Vaccination with inactivated vaccines is safe after transplantation and i

126 Experimental inactivated vaccines made with PWT/06 HPAI virus or rg-g

127 ody response to influenza A(H5N1) monovalent inactivated vaccine (MIV) among individuals for whom the

128 accine (n = 20), live-attenuated followed by inactivated vaccine (n = 15), twice AS03-adjuvanted inac

129 ated vaccine (n = 15), twice AS03-adjuvanted inactivated vaccine (n = 16) or placebo (n = 5, intranas

130 live-attenuated followed by AS03-adjuvanted inactivated vaccine (n = 20), live-attenuated followed b

131 piratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough

132 on-adjuvanted, chimeric H5/1, intramuscular, inactivated vaccine on day 85; the same regimen but with

133 naive mothers responded well to both DNA and inactivated vaccines, only DNA immunization induced effe

134 HXP-S can be administered intramuscularly as inactivated vaccine or intranasally as live vaccine.

135 ther one dose of CoronaVac (Sinovac Biotech; inactivated vaccine) or BNT162b2 (Fosun Pharma-BioNTech;

136 use model of coronavirus disease to evaluate inactivated vaccine performance against either homologou

137 sen for production of a monotypic, purified, inactivated vaccine (PIV).

138 ghly pathogenic avian H5N1 viruses, using an inactivated vaccine prepared from nonpathogenic A/Duck/S

139 ommon with live attenuated vaccine than with inactivated vaccine, primarily among children 6 to 11 mo

140 dy levels and outcome in human patients, and inactivated vaccines produce high titers of antibodies t

141 However, vaccination with an inactivated vaccine produces antibodies exclusively to t

142 lycoprotein Ags, neutralizing Abs induced by inactivated vaccines provide limited cross-protection ag

143 Inactivated vaccine provided marginal protection against

144 Live influenza vaccine and inactivated vaccine provided similar protection against

145 Current PRRS inactivated vaccine provides only a limited protection a

146 Intranasal immunization in mice with this inactivated vaccine provoked specific antibodies against

147 ttenuated vaccine recipients but only 23% of inactivated vaccine recipients demonstrated serologic co

148 Inactivated vaccines remain the principal intervention f

149 ccine with hydrogen peroxide; the chemically inactivated vaccine remained antigenic and protective in

150 This suggests that CD4 effectors induced by inactivated vaccine require high levels of cognate Ag re

151 of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenu

152 ighlight the impact of adjuvant selection on inactivated vaccine safety and efficacy against heterolo

153 Photochemically inactivated vaccine strains maintained a high degree of

154 Killed or inactivated vaccines targeting intracellular bacterial a

155 dered by previous experience with a formalin-inactivated vaccine that predisposed to a severe form of

156 e subtype IAB VEEV that were used to prepare inactivated vaccines that probably initiated several out

157 random-effects pooled efficacy for trivalent inactivated vaccine (TIV) and live attenuated influenza

158 n compared to that of the standard trivalent inactivated vaccine (TIV) in children with cancer.

159 eness of ATIV versus nonadjuvanted trivalent inactivated vaccine (TIV) in individuals at least 65 yea

160 body responses following influenza trivalent inactivated vaccine (TIV) vaccinations remains largely u

161 n (HA) were compared with standard trivalent inactivated vaccine (TIV).

162 uenza vaccine (MIIV) and 2010-2011 trivalent inactivated vaccine (TIV).

163 IV) while most others received the trivalent inactivated vaccine (TIV).

164 nrolled in a randomised trial (138 trivalent inactivated vaccine [TIV] and 145 placebo recipients).

165 ceived seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of eithe

166 the ability of a formaldehyde-treated, heat-inactivated vaccine to induce modest antibody responses

167 In contrast, the inability of inactivated vaccines to replicate enhances safety at the

168 The influenza vaccines were three seasonal, inactivated vaccines (trivalent, MF59C adjuvanted or a c

169 received a two-dose regimen of CoronaVac, an inactivated vaccine used globally.

170 to that induced by a facsimile of a formalin-inactivated vaccine used in previous clinical trials and

171 However, traditional inactivated vaccines used in animals are costly and have

172 n whether influenza A (H1N1) 2009 monovalent inactivated vaccines used in the USA increased the risk

173 nfection (VE(P) = 67%, 95% CI: 24, 100) than inactivated vaccine (VE(P) = 29%, 95% CI: -19, 76), alth

174 The effectiveness of inactivated vaccines (VE) against symptomatic and severe

175 %, 95% confidence interval (CI): 15, 66; for inactivated vaccine: VE(S) = 43%, 95% CI: 8, 79).

176 ved positivity because presumably the RNA of inactivated vaccine virus will not integrate into the ho

177 The absolute efficacy of the inactivated vaccine was 16% (95% confidence interval [CI

178 Immunization of females with an inactivated vaccine was also found to elicit a protectiv

179 imilar to those included in the vaccine, the inactivated vaccine was efficacious in preventing labora

180 In the 2007-2008 season, the inactivated vaccine was efficacious in preventing labora

181 of live attenuated vaccine, as compared with inactivated vaccine, was observed for both antigenically

182 ectiveness estimates for live attenuated and inactivated vaccine were 81% (95% CI, -37 to 97), and 58

183 ion against HAV using commercially available inactivated vaccine were compared in a Markov model anal

184 Influenza A (H1N1) 2009 monovalent inactivated vaccines were associated with a small increa

185 with a superior product profile to existing inactivated vaccines, which could lead to improved vacci

186 cosal and cell-mediated immunity better than inactivated vaccines while also requiring a smaller dose

187 We have shown that the cHA-inactivated vaccine with a squalene-based adjuvant induc

188 a single-dose immunization of ZIKV purified inactivated vaccine (ZPIV)(4-7) in a dengue virus (DENV)